Non-sedating antihistamine injection formulations and methods of use thereof
View Patent ↗Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions therewith.
1. A method for treating angioedema associated with an acute allergic reaction comprising:
administering to a patient in an emergency situation in need of such treatment an injection composition comprising racemic cetirizine or a pharmaceutically acceptable salt thereof, in an amount of effective to treat said angioedema associated with an acute allergic reaction,
wherein the injection composition is an aqueous solution having a pH of 3 to 9, and wherein administering comprises administration of 1 to 20 mg of racemic cetirizine.
2. The method of claim 1 , wherein said injection comprises:
about 0.1% to about 2% w/v of cetirizine or a pharmaceutically acceptable salt thereof;
about 0.1 to about 0.9% w/v NaCl;
with pH adjusted to about 3 to about 9; and Q.S. water.
3. The method of claim 1 , wherein said injection is an intravenous injection comprising:
about 1% w/v cetirizine or a pharmaceutically acceptable salt thereof;
about 0.65% w/v NaCl; and
adjusted to about pH 5.4;
in a 1 mL single dosage form.
4. The method of claim 1 , wherein administering the cetirizine injection while minimizes sedation, is free of hemolytic potential, and does not demonstrate an effect on the QTc interval.
5. The method of claim 1 , wherein administering is intravenous.
6. The method of claim 1 , wherein administering is intramuscular.
7. The method of claim 1 , wherein the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC 0-INF for the injectable composition to a logarithmic transformed geometric mean of AUC 0-INF for a reference oral product of cetirizine are 0.80 to 1.25.
8. The method of claim 1 , wherein the injectable composition of cetirizine has a 90% confidence interval around the difference in the reduction of at least one symptom of angioedema associated with an acute allergic reaction to a reference injectable formulation, for the per protocol evaluable population, within about −30.00 to about +30.00.
9. The method of claim 8 , wherein the reference injectable formulation is a 12.5-150 mg dose of a 50 mg/mL diphenydramine injectable formulation.
10. The method of claim 1 , wherein the injectable composition further comprises a second active agent comprising ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
11. The method of claim 1 , wherein the patient is a human or animal patient.
12. The method of claim 1 , wherein the acute allergic reaction is anaphylaxis.